DOCSLIB.ORG

Lymphoma: a Single-Arm, Open-Label, Phase 2 Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Haematologica HAEMATOL/2019/231076 Version 3 Haematologica HAEMATOL/2019/231076 Version 3 DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study Kana Miyazaki, Naoko Asano, Tomomi Yamada, Kohta Miyawaki, Rika Sakai, Tadahiko Igarashi, Momoko Nishikori, Kinya Ohata, Kazutaka Sunami, Isao Yoshida, Go Yamamoto, Naoki Takahashi, Masataka Okamoto, Hiroki Yano, Yuki Nishimura, Satoshi Tamaru, Masakatsu Nishikawa, Koji Izutsu, Tomohiro Kinoshita, Junji Suzumiya, Koichi Ohshima, Koji Kato, Naoyuki Katayama, Motoko Yamaguchi, and CD5+ DLBCL Treatment Study Group Collaborative Groups: CD5+ DLBCL Treatment Study Group) Haematologica HAEMATOL/2019/231076 Version 3 Disclosures: Disclosures KM received honoraria from Chugai Pharma, Kyowa Hakko Kirin, and Celgene; KM, NK, and MY received research funding from Sumitomo Group, Nippon Shinyaku, Chugai Pharma, Kyowa Hakko Kirin, Takeda, Astellas Pharma, Shionogi Pharmaceutical, Daiichi Sankyo, Eisai, Novartis, Pfizer, Teijin Pharma, Ono Pharmaceutical, Toyama Chemical Co, Mochida Pharmaceutical Co. Ltd., and Novo Nordisk; NA received honoraria from Takeda, Chugai Pharma, and Celgene; RS received honoraria from Chugai Pharma, Kyowa Hakko Kirin, Takeda, Ono Pharmaceutical, Eisai, Bayer, Bristol-Myers Squibb, Sumitomo Dainippon, Celgene, Mundipharma, and Janssen, research funding from Chugai Pharma, Kyowa Hakko Kirin, Takeda, Ono Pharmaceutical, Yakult Pharmaceutical, Taiho Pharmaceutical, and Eisai; TI received honoraria from Chugai Pharma and Kyowa Hakko Kirin, research funding from Zenyaku Kogyo, Sanofi, Eisai, Celltrion, and SymBio Pharmaceuticals; MN received honoraria from Eisai, Kyowa Hakko Kirin, Janssen, Ono Pharmaceutical, Chugai Pharma, MSD Japan, Pfizer, Takeda, and Sumitomo group, research funding from Eisai and Ono Pharmaceutical; KO received honoraria from Novartis, Kyowa Hakko Kirin, Shionogi Pharmaceutical, and Mochida Pharmaceutical Co. Ltd; KS received honoraria from Celgene, Ono Pharmaceutical, Takeda Pharmaceutical, and Bristol-Myers Squibb, research funding from Ono Pharmaceutical, MSD, Celgene, Abbvie, Takeda Pharmaceutical, Sanofi, Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Janssen Pharmaceutical, Alexion Pharma, and Daiichi Sankyo; IY received honoraria from Kyowa Hakko Kirin, Chugai Pharma, Celgene, Taiho Pharmaceutical, and Mundipharma International, research funding from Chugai Pharma and Kyowa Hakko Kirin; GY received honoraria form Kyowa Hakko Kirin, Celgene, Takeda, Bristol-Myers Squibb, Eisai, Janssen, Chugai Pharma, and Mundipharma, research funding from Eisai and Chugai Pharma; MO received honoraria from Eisai, Janssen, Ono Pharmaceutical, Bristol-Myers Squibb, Takeda, Chugai Pharma, Kyowa Hakko Kirin, Zenyaku Kogyo, and Mundipharma, research funding from Eisai, MSD, Pfizer, Novartis, Bristol-Myers Squibb, Ono Pharmaceutical, Takeda, Astellas Pharma, Sumitomo Dainippon, Taiho Pharmaceutical, Nippon Shinyaku, Teijin Pharma, and Asahi Kasei; ST received honoraria from Eisai and Chugai Pharma; MNishikawa received honoraria from Daiichi-Sankyo, consulting or advisory role from Daiichi-Sankyo; KI received honoraria from Takeda, Chugai, Eisai, Kyowa Hakko Kirin, Janssen, Ono Pharmaceutical, Gilead Sciences, Abbvie, MSD, Novartis, Nihon Medi-Physics, Daiichi Sankyo, Otsuka, Mundhipharma, Bayer, Meiji Seika Kaisha, Shionogi Pharma, Astellas Pharma, Asahi Kasei, and Bristol-Myers Squibb, consulting or advisory role from Bayer and Celgene, research funding from Abbvie, Astellas Pharma, Amgen, Bayer, Celgene, Celltrion, Chugai Pharma, Daiichi Sankyo, Eisai, HUYA Bioscience International, Janssen, Ono Pharmaceutical, Sanofi, Solasia Pharma, SymBio Pharmaceuticals, Takeda, and Zenyaku Kogyo; TI received honoraria from Eisai, Kyowa Hakko Kirin, Zenyaku Kogyo, Chugai Pharma, Janssen, Ono Pharmaceutical, Gilead Sciences, and Takeda, research funding from Gilead Sciences, Solasia Pharma, and Chugai Pharma; JS received from honoraria from Chugai Pharma, Kyowa Hakko Kirin, Janssen, Eisai, Takeda, Celgene, and Bristol Myers Squibb, consulting or advisory role from Celgene, Jansen, Abbvie, and Zenyaku Kogyo, research funding from Kyowa Hakko Kirin, Chugai-Roche, Eisai, Takeda, Sumitomo Dainippon, Taiho Pharmaceutical, Pfizer, Celltrion, and SymBio Pharmaceuticals; KO received honoraria from Chugai Pharma and Kyowa Hakko Kirin, consulting or advisory role from SRL, research funding from Chugai Pharma and Kyowa Hakko Kirin; KK received honoraria from Chugai Pharma, Takeda, MSD, Kyowa Hakko Kirin, Janssen, Celgene, Ono Pharmaceutical, Mundipharma, and Sumitomo Group, research funding from Chugai Pharma, Takeda, Kyowa Hakko Kirin, Abbvie, Novartis, Eisai, Janssen, Celgene, and Ono Pharmaceutical; NK received honoraria from Sumitomo Group, Nippon Shinyaku, Chugai Pharma, Kyowa Hakko Kirin, Taisho Toyama Pharma, Celgene, Alexion Pharmaceuticals, Shire, Takeda, Astellas Pharma, Shionogi Pharmaceutical, Novartis, Janssen, Pfizer, Sysmex, Novo Nordisk, and Bristol-Myers Squibb; MY received honoraria from Chugai Pharma, Eisai, Takeda, Nippon Shinyaku, Kyowa Hakko Kirin, Teijin Pharma, Meiji Seika Kaisha, Celgene, and Bristol-Myers Squibb. The other authors have no relationship to disclose. Haematologica HAEMATOL/2019/231076 Version 3 Contributions: Contributions KM contributed to the conception and design of the study, provision of study materials or patients, collection and assembly of data, data analysis and interpretation, and writing of the first draft. NA, KMiyawaki, YN, KO, and KK contributed to the collection and assembly of data. TY contributed to the conception and design of the study, data analysis and interpretation. KI and JS contributed to the conception and design of the study, provision of study materials or patients, data analysis and interpretation. RS, TI, MN, KO, KS, IY, GY, NT, MO, and HY contributed to provision of study materials or patients. ST contributed to the conception and design of the study. TK contributed to the conception and design of the study, data analysis and interpretation. MNishikawa contributed to the data analysis and interpretation. NK contributed to the administrative support. MY contributed to the conception and design of the study, financial support, provision of study materials or patients, data analysis and interpretation. All authors have read and approved the final manuscript. Study investigators S Ichikawa, N Fukuhara, Y Hasegawa, Y Obara, S Chiba, S Akio, K Toyama, A Wake, A Yokoyama, T Kagoo, T Yano, Y Isobe, K Tsukasaki, M Kohri, H Takasaki, N Tomita, K Matsumoto, E Matsuura, M Tanabe, Y Masaki, M Saori, Y Kumano, N Iwaki, A Sawazaki, A Okamoto, Y Inaguma, A Asano, E Takeshige; T Kitano; T Kodaka, H Tsunemine, T Takahashi, M Makita, T Takahashi, Y Suehiro, I Choi, T Matsunaga, A Kada, N Usui, N Fujihara, T Sugio, K Sasaki, K Akashi .
Recommended publications
  • Nilotinib in Patients with Chronic Myeloid Leukemia: STAT2 Trial in Japan

    Nilotinib in Patients with Chronic Myeloid Leukemia: STAT2 Trial in Japan

    Haematologica HAEMATOL/2018/194894 Version 3 Haematologica HAEMATOL/2018/194894 Version 3 Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan Naoto Takahashi, Kaichi Nishiwaki, Chiaki Nakaseko, Nobuyuki Aotsuka, Koji Sano, Chikako Ohwada, Jun Kuroki, Hideo Kimura, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Saori Takahashi, Yoshihiro Kameoka, Hiroyoshi Nishikawa, and Hisashi Wakita Disclosures: 1. This study was supported by research funding from Novartis Pharmaceuticals to N.T. 2. N.T reports grants from Novartis Pharmaceuticals, during the conduct of the study; grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Otsuka, grants and personal fees from Pfizer, personal fees from Bristol-Myers Squibb, outside the submitted work; K.N reports grants from Zenyaku Kogyo Company, Limited, grants from Chugai Pharmaceutical, grants from Novartis Pharma K.K., grants from Kyowa Hakko Kirin Co, Ltd, grants from Nippon Shinyaku Co, Ltd, outside the submitted work; C.N reports personal fees from Novartis, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Pfizer, grants and personal fees from Takeda pharmaceuticals, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Otsuka Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Asahi Kasei Pharma, grants and personal fees from Shionogi, personal fees from Shire, personal fees from Jannsen, personal fees from Celgene, outside the submitted work; M.T. reports personal fees from Bristol-Myers Squib, personal fees from Pfizer, outside the submitted work; K.M reports grants from Kyowa Hakko Kirin Co.
  • 1332 Nippon Suisan Kaisha, Ltd. 50 1333 Maruha Nichiro Corp. 500 1605 Inpex Corp

    1332 Nippon Suisan Kaisha, Ltd. 50 1333 Maruha Nichiro Corp. 500 1605 Inpex Corp

    Nikkei Stock Average - Par Value (Update:August/1, 2017) Code Company Name Par Value(Yen) 1332 Nippon Suisan Kaisha, Ltd. 50 1333 Maruha Nichiro Corp. 500 1605 Inpex Corp. 125 1721 Comsys Holdings Corp. 50 1801 Taisei Corp. 50 1802 Obayashi Corp. 50 1803 Shimizu Corp. 50 1808 Haseko Corp. 250 1812 Kajima Corp. 50 1925 Daiwa House Industry Co., Ltd. 50 1928 Sekisui House, Ltd. 50 1963 JGC Corp. 50 2002 Nisshin Seifun Group Inc. 50 2269 Meiji Holdings Co., Ltd. 250 2282 Nh Foods Ltd. 50 2432 DeNA Co., Ltd. 500/3 2501 Sapporo Holdings Ltd. 250 2502 Asahi Group Holdings, Ltd. 50 2503 Kirin Holdings Co., Ltd. 50 2531 Takara Holdings Inc. 50 2768 Sojitz Corp. 500 2801 Kikkoman Corp. 50 2802 Ajinomoto Co., Inc. 50 2871 Nichirei Corp. 100 2914 Japan Tobacco Inc. 50 3086 J.Front Retailing Co., Ltd. 100 3099 Isetan Mitsukoshi Holdings Ltd. 50 3101 Toyobo Co., Ltd. 50 3103 Unitika Ltd. 50 3105 Nisshinbo Holdings Inc. 50 3289 Tokyu Fudosan Holdings Corp. 50 3382 Seven & i Holdings Co., Ltd. 50 3401 Teijin Ltd. 250 3402 Toray Industries, Inc. 50 3405 Kuraray Co., Ltd. 50 3407 Asahi Kasei Corp. 50 3436 SUMCO Corp. 500 3861 Oji Holdings Corp. 50 3863 Nippon Paper Industries Co., Ltd. 500 3865 Hokuetsu Kishu Paper Co., Ltd. 50 4004 Showa Denko K.K. 500 4005 Sumitomo Chemical Co., Ltd. 50 4021 Nissan Chemical Industries, Ltd. 50 4042 Tosoh Corp. 50 4043 Tokuyama Corp. 50 WF-101-E-20170803 Copyright © Nikkei Inc. All rights reserved. 1/5 Nikkei Stock Average - Par Value (Update:August/1, 2017) Code Company Name Par Value(Yen) 4061 Denka Co., Ltd.
  • View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0

    View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0

    Katakami et al. Cardiovasc Diabetol (2020) 19:110 https://doi.org/10.1186/s12933-020-01079-4 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Tofoglifozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3 and Iichiro Shimomura1 on behalf of the UTOPIA study investigators Abstract Background: This study aimed to investigate the preventive efects of tofoglifozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT). Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofoglifozin treatment group (n 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n 171). Primary outcomes were changes= in mean and maximum common carotid IMT measured by echography during= a 104-week treatment period. Results: In a mixed-efects model for repeated measures, the mean IMT of the common carotid artery (mean- IMT-CCA), along with the right and left maximum IMT of the CCA (max-IMT-CCA), signifcantly declined in both the tofoglifozin ( 0.132 mm, SE 0.007; 0.163 mm, SE 0.013; 0.170 mm, SE 0.020, respectively) and the control group ( 0.140 mm,− SE 0.006; 0.190 mm,− SE 0.012; 0.190 mm,− SE 0.020, respectively).
  • FTSE Japan ESG Low Carbon Select

    FTSE Japan ESG Low Carbon Select

    2 FTSE Russell Publications 19 August 2021 FTSE Japan ESG Low Carbon Select Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country ABC-Mart 0.01 JAPAN Ebara 0.17 JAPAN JFE Holdings 0.04 JAPAN Acom 0.02 JAPAN Eisai 1.03 JAPAN JGC Corp 0.02 JAPAN Activia Properties 0.01 JAPAN Eneos Holdings 0.05 JAPAN JSR Corp 0.11 JAPAN Advance Residence Investment 0.01 JAPAN Ezaki Glico 0.01 JAPAN JTEKT 0.07 JAPAN Advantest Corp 0.53 JAPAN Fancl Corp 0.03 JAPAN Justsystems 0.01 JAPAN Aeon 0.61 JAPAN Fanuc 0.87 JAPAN Kagome 0.02 JAPAN AEON Financial Service 0.01 JAPAN Fast Retailing 3.13 JAPAN Kajima Corp 0.1 JAPAN Aeon Mall 0.01 JAPAN FP Corporation 0.04 JAPAN Kakaku.com Inc. 0.05 JAPAN AGC 0.06 JAPAN Fuji Electric 0.18 JAPAN Kaken Pharmaceutical 0.01 JAPAN Aica Kogyo 0.07 JAPAN Fuji Oil Holdings 0.01 JAPAN Kamigumi 0.01 JAPAN Ain Pharmaciez <0.005 JAPAN FUJIFILM Holdings 1.05 JAPAN Kaneka Corp 0.01 JAPAN Air Water 0.01 JAPAN Fujitsu 2.04 JAPAN Kansai Paint 0.05 JAPAN Aisin Seiki Co 0.31 JAPAN Fujitsu General 0.01 JAPAN Kao 1.38 JAPAN Ajinomoto Co 0.27 JAPAN Fukuoka Financial Group 0.01 JAPAN KDDI Corp 2.22 JAPAN Alfresa Holdings 0.01 JAPAN Fukuyama Transporting 0.01 JAPAN Keihan Holdings 0.02 JAPAN Alps Alpine 0.04 JAPAN Furukawa Electric 0.03 JAPAN Keikyu Corporation 0.02 JAPAN Amada 0.01 JAPAN Fuyo General Lease 0.08 JAPAN Keio Corp 0.04 JAPAN Amano Corp 0.01 JAPAN GLP J-REIT 0.02 JAPAN Keisei Electric Railway 0.03 JAPAN ANA Holdings 0.02 JAPAN GMO Internet 0.01 JAPAN Kenedix Office Investment Corporation 0.01 JAPAN Anritsu 0.15 JAPAN GMO Payment Gateway 0.01 JAPAN KEWPIE Corporation 0.03 JAPAN Aozora Bank 0.02 JAPAN Goldwin 0.01 JAPAN Keyence Corp 0.42 JAPAN As One 0.01 JAPAN GS Yuasa Corp 0.03 JAPAN Kikkoman 0.25 JAPAN Asahi Group Holdings 0.5 JAPAN GungHo Online Entertainment 0.01 JAPAN Kinden <0.005 JAPAN Asahi Intecc 0.01 JAPAN Gunma Bank 0.01 JAPAN Kintetsu 0.03 JAPAN Asahi Kasei Corporation 0.26 JAPAN H.U.
  • Factset-Top Ten-0521.Xlsm

    Factset-Top Ten-0521.Xlsm

    Pax International Sustainable Economy Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight ASML Holding NV 34,391,879.94 4.3 Roche Holding Ltd 28,162,840.25 3.5 Novo Nordisk A/S Class B 17,719,993.74 2.2 SAP SE 17,154,858.23 2.1 AstraZeneca PLC 15,759,939.73 2.0 Unilever PLC 13,234,315.16 1.7 Commonwealth Bank of Australia 13,046,820.57 1.6 L'Oreal SA 10,415,009.32 1.3 Schneider Electric SE 10,269,506.68 1.3 GlaxoSmithKline plc 9,942,271.59 1.2 Allianz SE 9,890,811.85 1.2 Hong Kong Exchanges & Clearing Ltd. 9,477,680.83 1.2 Lonza Group AG 9,369,993.95 1.2 RELX PLC 9,269,729.12 1.2 BNP Paribas SA Class A 8,824,299.39 1.1 Takeda Pharmaceutical Co. Ltd. 8,557,780.88 1.1 Air Liquide SA 8,445,618.28 1.1 KDDI Corporation 7,560,223.63 0.9 Recruit Holdings Co., Ltd. 7,424,282.72 0.9 HOYA CORPORATION 7,295,471.27 0.9 ABB Ltd. 7,293,350.84 0.9 BASF SE 7,257,816.71 0.9 Tokyo Electron Ltd. 7,049,583.59 0.9 Munich Reinsurance Company 7,019,776.96 0.9 ASSA ABLOY AB Class B 6,982,707.69 0.9 Vestas Wind Systems A/S 6,965,518.08 0.9 Merck KGaA 6,868,081.50 0.9 Iberdrola SA 6,581,084.07 0.8 Compagnie Generale des Etablissements Michelin SCA 6,555,056.14 0.8 Straumann Holding AG 6,480,282.66 0.8 Atlas Copco AB Class B 6,194,910.19 0.8 Deutsche Boerse AG 6,186,305.10 0.8 UPM-Kymmene Oyj 5,956,283.07 0.7 Deutsche Post AG 5,851,177.11 0.7 Enel SpA 5,808,234.13 0.7 AXA SA 5,790,969.55 0.7 Nintendo Co., Ltd.
  • Daiichi Sankyo Company, Limited

    Daiichi Sankyo Company, Limited

    [Translation] CONVOCATION NOTICE OF THE 14TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Year Ended March 31, 2019 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts etc. originally issued in the Japanese version. - 1 - [Translation] To Our Shareholders At the Daiichi Sankyo Group (“the Group”), we are proceeding with the initiatives of 4th mid- term business plan with the aim of becoming a “Global Pharma Innovator with Competitive Advantage in Oncology” as set forth in our 2025 Vision. In fiscal 2018, we made significant progress in developing new drugs in oncology area, including DS-8201, an antibody drug conjugates utilizing our proprietary technologies. In addition, we entered into a strategic collaboration agreement with AstraZeneca, which has strengths in the oncology business, for the global development and commercialization of DS-8201 in order to maximize its value. Furthermore, sales of mainstay products such as edoxaban, an anticoagulant which supports current earnings of the Group, were firm in Japan and overseas. The achievement of initial target of mid-term business plan for fiscal 2020 is expected to be delayed by two years due to failure of achievement of the plan for pain franchise business and additional investments in research and development. However, we are gaining confidence of achieving our 2025 Vision and accelerating growth in the future due to the significant improvement in the value of oncology area pipelines. We will continue to make every effort to achieve the goals of the Medium-Term Management Plan and 2025 Vision. I greatly appreciate your continued support in the future.
  • Daiichi Sankyo Group Value Report 2019

    Daiichi Sankyo Group Value Report 2019

    External Evaluations (as of June 30,2019) ™ Daiichi Sankyo Group Value Report 2019 Value Daiichi Sankyo Group MSCI Japan Empowering Women Select Index THE INCLUSION OF DAIICHI SANKYO CO.,LTD. IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF DAIICHI SANKYO CO.,LTD. BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADE- MARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES. “Eruboshi” Certification Mark “Kurumin” Certification Mark Logo given to Certified Health and Productivity Management Organization (White500) This report uses FSC® certified paper, which indicates that the paper used to print this Paper report was produced from properly managed forests. 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan This report was printed using 100% Inks biodegradable printing inks from vegetable Corporate Communications Department oil. Daiichi Sankyo Group Tel: +81-3-6225-1126 CSR Department The waterless printing method used for this Value Report 2019 Tel: +81-3-6225-1067 Printing report minimized the use and release of harmful liquid wastes. https://www.daiichisankyo.com/ Printed in Japan 005_7045687911909.indd 1 2019/09/27 18:22:19 Introduction Our Mission The Core Values and Commitments serve as the criteria for business activities and In addition, we have established the DAIICHI SANKYO Group Corporate Conduct Charter . decision-making used by executive officers and employees in working to fulfill Our Mission . This charter calls on us to fulfill our social responsibilities by acting with the highest ethical Our Corporate Slogan succinctly explains the spirit of Our Mission, Core Values and standards and a good social conscience appropriate for a company engaged in business Commitments.
  • Sumitomo Chemical 100 Years Sumitomo Chemical 100 Years Published: August 2014 Published by Sumitomo Chemical Co.,Ltd

    Sumitomo Chemical 100 Years Sumitomo Chemical 100 Years Published: August 2014 Published by Sumitomo Chemical Co.,Ltd

    Sumitomo Chemical 100 Years Sumitomo Chemical 100 Years Published: August 2014 Published by Sumitomo Chemical Co.,Ltd. Production and editing : Sumitomo Chemical Co.,Ltd., Corporate History Editorial Office 27-1, Shinkawa 2-chome, Chuo-ku, Tokyo, Japan Production assisted by Dai Nippon Printing Co.,Ltd. Printed in Japan by Dai Nippon Printing Co.,Ltd. CONTENTS Chairman’s Message President’s Message The Path to a Global Chemical Company 1. The History of Sumitomo 8 2. History of Sumitomo Fertilizer Works 10 3. Going from a Fertilizer Manufacturer to a Chemical Company 14 4. Moving into Fine Chemicals 16 5. Post-war Recovery 18 6. Moving into the Agricultural Chemicals Business 20 7. Growth of the Pharmaceuticals Sector 22 8. Entering the Field of Petrochemicals 24 9. Dealing with the Oil Crises 26 10. Rise and Decline of Aluminum Business 28 11. Construction of Singapore Petrochemical Complex 32 12. Separation of Pharmaceutical Business from Sumitomo Chemical and Inauguration 34 of Dainippon Sumitomo Pharma Co., Ltd. 13. Expansion of Agricultural Chemicals Business 36 14. IT-related Chemicals Sector Established and Business Grows 38 15. Progress of the Rabigh Project 40 16. Aiming to be a Truly Global Chemical Company 42 17. For a Better Tomorrow 46 Reports from Regional Headquarters 48 Report from Beijing by Sumitomo Chemical (China) Co., Ltd. 48 Report from Singapore by Sumitomo Chemical (Asia Pacific) Pte Ltd 50 Report from Brussels by Sumitomo Chemical Europe S.A./N.V. 52 Report from New York by Sumitomo Chemical America, Inc. 54 The Sumitomo Spirit and Sumitomo Chemical’s Business Philosophy 56 Recent Sales and Profits 57 Sumitomo Chemical Locations in Japan 58 Major Companies of Sumitomo Chemical Group: Japan 59 Major Companies of Sumitomo Chemical Group: International 60 Chronology of Sumitomo Chemical 62 Chairman’s Message In October 2015, Sumitomo Chemical will cele- triggered by the fall of Lehman Brothers and the sub- brate its 100 year anniversary.
  • ALEXION PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)

    ALEXION PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 ALEXION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-27756 13-3648318 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 121 Seaport Boulevard, Boston, Massachusetts 02210 (Address of principal executive offices, including zip code) (475) 230-2596 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Trading Name of each exchange Title of each class Symbol on which registered Common Stock, par value $0.0001 per share ALXN The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
  • Convocation Notice of the 16Th Ordinary General Meeting of Shareholders

    Convocation Notice of the 16Th Ordinary General Meeting of Shareholders

    [Translation] CONVOCATION NOTICE OF THE 16TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Year Ended March 31, 2021 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts etc. originally issued in the Japanese version. [Translation] To Our Shareholders We sincerely appreciate the continuous kindness of our shareholders. In addition, we would like to express our deepest sympathies to those who passed away due to COVID-19, and thank the medical personnel who are close to those who are fighting illness and are making efforts in treatment. We will continue to devote ourselves to the research and development of vaccines and therapeutic agents. Our “Purpose” is to “contribute to the enrichment of quality of life around the world.” As a pharmaceutical company with strengths in science and technology, we continuously create innovative pharmaceuticals and provide pharmaceuticals that meet diverse medical needs to provide sustainable value to society. We were able to launch the anti-cancer drug “Enhertu”, which is an antibody-drug conjugate (ADC) that utilizes our unique technology, in Japan and Europe in fiscal 2020, following the launch in the U.S. in fiscal 2019. Subsequent ADCs such as Dato-DXd and HER3-DXd are also steadily developing. Now, we have newly established our 2030 Vision of being an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society,” and have established 5-Year Business Plan (fiscal 2021 to fiscal 2025) as a plan to realize our 2025 Vision, “Global Pharma Innovator with Competitive Advantage in Oncology.” By working together as a Daiichi Sankyo Group on 5-Year Business Plan toward the 2030 Vision, we aim to solve the social issues expected of our company and increase shareholder value.
  • 1976 3M Medical Solutions Division 2019 Electrocore, Inc. 2019 Optinose 1985 Abbott Laboratories, Inc

    1976 3M Medical Solutions Division 2019 Electrocore, Inc. 2019 Optinose 1985 Abbott Laboratories, Inc

    CURRENT SUSTAINING MEMBER COMPANIES MEMBER FOR OVER: 10 Years 25 Years 50 Years Member Since (alphabetical order) 1976 3M Medical Solutions Division 2019 electroCore, Inc. 2019 Optinose 1985 Abbott Laboratories, Inc. 2010 Endo Pharmaceuticals 2018 Organogenesis 2013 AbbVie Inc. 2017 Exelixis 2004 Otsuka America Pharmaceutical, Inc. 2021 Adaptive Biotechnologies 2016 Express Scripts Federal Pharmacy 2018 Pacira BioSciences, Inc. 2017 ACADIA Pharmaceuticals, Inc. 2010 Federal Practitioner 2018 Paratek Pharmaceuticals 2020 AcelRx Pharmaceuticals, Inc. 2018 Foundation Medicine, Inc. 1990 Pfizer Pharmaceuticals 2020 Acorda Therapeutics 2021 Frontier Technology Inc. (FTI) 2017 Pharmacyclics, LLC 2019 Aimmune 2020 Fresenius Medical Care North America 2020 RedHill BioPharma 2003 Alcon Laboratories, Inc. 1989 Genentech Inc. 2019 Red One Medical 2019 Alexion Pharmaceuticals, Inc. 2006 Gilead Sciences 2020 Regeneron 2017 Alkermes, Inc. 1983 GLAXOSMITHKLINE 2009 Regenesis Biomedical, Inc. 2019 Alnylam Pharmaceuticals 2013 Golden State Medical Supply, Inc. 2011 Remund Group, LLC 2019 Altarum Institute 2020 GRAIL 2018 Rigel Pharmaceuticals 2020 Amarin Corporation 2019 Greenwich Biosciences 2000 Sanofi 1994 AmerisourceBergen 2013 Gulf Coast Pharmaceuticals Plus, LLC 2020 Seattle Genetics 1992 Amgen 2008 Heritage Health Solutions, Inc. 2004 Siemens Medical Solutions 2020 Amneal Pharmaceutical 2017 Hill-Rom Company 2019 SK Life Science, Inc. 2019 Aptive Resources LLC 2020 Immunomedics 2002 Smith & Nephew, Inc. 2020 The Arbinger Institute 2019 ImmunoVation, LLC 2019 Sobi Inc. 2011 Arbor Pharmaceuticals, LLC 2019 Incyte Corporation 2013 Stryker Orthopaedics 2010 Argentum Medical, LLC 2019 Indivior 2018 Sun Pharmaceutical 2019 ASM Research, LLC 2015 Intercept Pharmaceuticals 1999 Sunovion Pharmaceuticals, Inc. 1986 Astellas Pharma US, Inc. 2019 Ipsen Biopharmaceuticals, Inc. 2016 Taiho Oncology, Inc. 1995 AstraZeneca 2018 IT Cadre 2015 Takeda Oncology 2020 Baudax Bio, Inc.
  • Research and Development in Breast Ultrasound E

    Research and Development in Breast Ultrasound E

    E. Ueno, T. Shiina, M. Kubota, K. Sawai (Eds.) Research and Development in Breast Ultrasound E. Ueno, T. Shiina M. Kubota, K. Sawai (Eds.) Research and Development in Breast Ultrasound With 150 Figures, Including 37 in Color 1 3 Ei Ueno, M.D., Ph.D. Associate Professor, Department of Breast-Thyroid-Endocrine Surgery Institute of Clinical Medicine, University of Tsukuba 1-1-1 Tennodai, Tsukuba, Ibaraki 304-8573, Japan Tsuyoshi Shiina, Ph.D. Professor, Institute of Information Sciences and Electronics, University of Tsukuba 1-1-1 Tennodai, Tsukuba, Ibaraki 304-8573, Japan Mitsuhiro Kubota, M.D. Director of Yamachika Memorial Hospital 3-19-14 Koyawata, Odawara, Kanagawa 256-0815, Japan Kiyoshi Sawai, M.D. Associate Professor, Department of Endocrine & Breast Surgery Kyoto Prefectural University of Medicine 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-0841, Japan Cover Illustration: Madoka Momota Library of Congress Control Number: 2004116202 ISBN 4-431-40277-2 Springer-Verlag Tokyo Berlin Heidelberg New York This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broad- casting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and appli- cation thereof contained in this book.